reference/10726680

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10726680

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural
endingPage	1909
issn	1557-3265 1078-0432
issueIdentifier	7
pageRange	1900-1909
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	1900
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_969c8b07ac1b3b3f1a20ca36a5d4adc8 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ae90c8435cdd1d8ca3c7b4a8a049d815 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4d74a9317ab6ec3ce255edb4b6cabead
bibliographicCitation	Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 01;20(7):1900–9. doi: 10.1158/1078-0432.ccr-13-1710. PMID: 24523439.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f39454feff22676a0cc19a2880acdce8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cca756ca1dc46fdf916390a3eb32df55 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d44b1ddbdc872461d017b55415321126 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de42f3ce31cf6da50179fcb307f24070 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c9eefce1e2245a5fa89cc25b9dfb3237 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47af0662b55662444020a233e44bfffc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e863e8ef9959503e609339333914781f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6aca486f7d9d57b3b29fbbef009659ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9b56c415ee0f973e72b149ab0c829c5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c6318002c14652d33bbed79f5f01e04a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e077ca4f53fb348611ae21b15deb627b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8682bf126c41bf0f3c5709be70f92510 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_554ed929bf5d3d57e0cde6a89364e119 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1f435971325c46f94a870e7a078901e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a67052f5b5bb0271affba3ed5e4d46be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2282291a96b914e9a163dc975fd5cef5
date	2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/24523439 https://doi.org/10.1158/1078-0432.ccr-13-1710
isPartOf	https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
discusses	http://id.nlm.nih.gov/mesh/M0351340 http://id.nlm.nih.gov/mesh/M0018233 http://id.nlm.nih.gov/mesh/M000616322 http://id.nlm.nih.gov/mesh/M0453087 http://id.nlm.nih.gov/mesh/M000615302 http://id.nlm.nih.gov/mesh/M0021788 http://id.nlm.nih.gov/mesh/M0002570 http://id.nlm.nih.gov/mesh/M000598380 http://id.nlm.nih.gov/mesh/M0443139
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001713Q000008 http://id.nlm.nih.gov/mesh/D043562Q000037 http://id.nlm.nih.gov/mesh/D008527Q000188 http://id.nlm.nih.gov/mesh/D002280Q000188 http://id.nlm.nih.gov/mesh/D011725Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000072086 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008527Q000235 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D043562Q000235 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D001713Q000493 http://id.nlm.nih.gov/mesh/D014157Q000096 http://id.nlm.nih.gov/mesh/D008527Q000473 http://id.nlm.nih.gov/mesh/D015972Q000187 http://id.nlm.nih.gov/mesh/D002280Q000235 http://id.nlm.nih.gov/mesh/D002280Q000473 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D015398 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D011725Q000009 http://id.nlm.nih.gov/mesh/D001713Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000071676 http://id.nlm.nih.gov/mesh/D011725Q000493 http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_901efdb0bee100f33f3cae3d9bfcb998 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7159 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7512 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.3.2 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11437 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6847 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_72f7539a175d2fbcabce2fc736b88f11 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24775005 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9262 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8443

Total number of triples: 92.